669 results on '"DEL PRATO, Stefano"'
Search Results
2. Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy
3. Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study
4. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
5. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
6. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk
7. The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe
8. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
9. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
11. The relationship between dietary patterns and glycemic variability in people with impaired glucose tolerance
12. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
13. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
14. Glucose tolerance and markers of myocardial injury after an acute coronary syndrome: predictive role of the 1-h plus 2-h plasma glucose at the oral glucose tolerance test
15. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis
16. Women in diabetes research: we can do better. Reply to Bonnefond A [letter]
17. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin
18. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk
19. Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future
20. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
21. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
22. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
23. Altered Visual Plasticity in Morbidly Obese Subjects
24. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
25. How conclusive is the CONCLUDE trial?
26. Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT‐proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC
27. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
28. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
29. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
30. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
31. Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
32. EFFECTS OF ALBIGLUTIDE ON TYPES AND NUMBERS OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE HARMONY OUTCOMES TRIAL
33. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP:A clinical consensus statement from the Heart Failure Association of the ESC
34. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis
35. Women in diabetes research: we can do better. Reply to Bonnefond A [letter]
36. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus
37. Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus
38. Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]
39. 422-P: Predictive Role of Triglyceride-Glucose Index on All-Cause Mortality and Incidence of Vascular Events in Type 2 Diabetes (T2D) : A 13-Year Follow-Up Observational Study
40. 97-OR: Fatty Liver Index (FLI) Is an Independent Risk Factor for All-Cause Mortality and Cardiovascular Events in Type 1 Diabetes (T1D) : A 10-Year Observational Study
41. 258-OR: Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
42. 749-P: Clinically Relevant Predictors of Cardiovascular Events: Exploratory Analysis from the VERIFY Study of Initial Treatment of Type 2 Diabetes Mellitus
43. 54-LB: Distinct Mechanisms Are Responsible for the Increase in Endogenous Glucose Production and Ketone Formation following Empagliflozin in T2DM Patients
44. 90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials
45. Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
46. The incretin/glucagon system as a target for pharmacotherapy of obesity
47. Additional file 1 of Glucose tolerance and markers of myocardial injury after an acute coronary syndrome: predictive role of the 1-h plus 2-h plasma glucose at the oral glucose tolerance test
48. Telemonitoring, Telemedicine and Time in Range During the Pandemic
49. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists
50. COVID-19, Hyperglycemia, and New-Onset Diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.